arrow Log In to View Account     |          
UTASIP
UTASIP Logo
 

Based on the proceedings of a symposium held at the
Academy of Managed Care Pharmacy’s 23rd Annual Meeting and Showcase

OVERVIEW
Hepatitis C virus (HCV) infection is a global and national health issue, affecting an estimated 170 million people worldwide and over 3 million people in the United States. Approximately 80% of infected individuals will develop chronic HCV infection, which may result in substantial morbidity and mortality due to the development of hepatic fibrosis, liver cirrhosis, and hepatocellular carcinoma. Despite the current therapeutic options, up to 60% of patients with HCV genotype 1 infection do not clear virus. Several therapeutic strategies are currently undergoing investigation. The role of novel therapeutic strategies in the treatment of HCV infection will be determined based on their efficacy, related adverse events, and resistance profiles.

Managed care pharmacists are in a unique position and often work directly with physicians and other caregivers to determine which medical treatments are most effective in enhancing patient outcomes. This activity has been designed to specifically meet the needs of managed care pharmacists and will provide participants with the latest advances in the management of HCV infection, including the burden of disease, the importance of achieving a sustained virologic response, and the economic impact on healthcare resources.

GOAL
This enduring material has been designed to provide managed care pharmacists with up-to-date information on the diagnosis and management of HCV.

INTENDED AUDIENCE
This activity is designed for managed care pharmacists. No prerequisites required.

LEARNING OBJECTIVES
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:

  • Discuss factors that comprise the burden of disease associated with HCV infection.
  • Identify risk factors for HCV infection to determine who should be screened.
  • Develop individualized management plans for patients with HCV infection, including the use of surrogate virologic parameters to determine if treatment should be continued or if virologic cure has been achieved.
  • Implement strategies for improving adherence in patients with HCV infection.
  • Assess the potential role of agents in development for the management of patients with HCV infection.

ACCREDITATION STATEMENT
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.

CREDIT DESIGNATION STATEMENT
acpe logoThe University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based educational activity will provide a statement for 1.5 contact hours credit (0.15 CEUs) and will be available for download following successful completion of the activity. Successful completion includes taking the pre-test, participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination one more time. ACPE Program #0064-0000-11-202-H01-P.

This continuing pharmacy education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean for Continuing Pharmacy Education, University of Tennessee College of Pharmacy.

The estimated time to complete this educational activity: 1.5 hours.

Release date: June 15, 2011; Expiration date: June 15, 2013.

FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The faculty reported the following:

Jason P. Smith, PharmD (Chair)
Clinical Pharmacy Specialist
Department of Pharmacy
Greater Los Angeles Veterans Affairs Healthcare System
West Los Angeles VA Medical Center
Los Angeles, California
Dr Smith reports holding stock in Vertex Pharmaceuticals

Pamela S. Belperio, PharmD, BCPS
National Public Health Clinical Pharmacist
Center for Quality Management in Public Health
Department of Veterans Affairs
Los Angeles, California
Dr Belperio reports having no significant financial or advisory relationships with corporate organizations related to this activity.

Christine Pocha, MD, PhD
Assistant Professor of Medicine, University of Minnesota
Co-Director, Minneapolis Hepatitis C Resource Center
Staff Hepatologist, GI Department
Minneapolis VA Health Care System
Minneapolis, Minnesota
Dr Pocha reports serving as a consultant for Three Rivers Pharmaceuticals.

OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the participants of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

DISCLAIMER STATEMENT
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.

GRIEVANCE POLICY
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an educational activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

FEE INFORMATION
There is no fee for this educational activity.

CLINICAL SLIDE LIBRARY
Instructions
Please complete the pre-test, listen to the following presentations, and complete the post-test and evaluation to receive CPE credit for this activity.

PRE-ASSESSMENT

PRESENTATIONS
Introduction
Jason P. Smith, PharmD

HCV Infection and Burden of Disease
Christine Pocha, MD, PhD

Managing HCV Infection: Examining the Evolving Treatment Landscape
Pamela S. Belperio, PharmD, BCPS

The Need for Pharmacist Involvement in Managing Patients with Hepatitis C
Jason P. Smith, PharmD

Final Remarks
Jason P. Smith, PharmD

POST-ASSESSMENT

Supported by an educational grant from Vertex Pharmaceuticals

procced to pretest
University of Tennessee Advanced Studies in Pharmacy (ISSN-1558-0350), is published by Galen Publishing, LLC, d/b/a ASiM, PO Box 340, Somerville, NJ 08876. (908) 253-9001. Copyright ©2012 by Galen Publishing. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of The Healthcare Media Group, LLC.